Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Severe and Enduring Anorexia Nervosa
NCT03928808Phase 1Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in anorexia nervosa (AN), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Proportion of Participants with Adverse Events (AEs) at Day 30, Proportion of Participants with a Severe Adverse Event (SAE) at Day 30 and 3 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
allogeneic fecal microbiota
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on NCT03928808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928808.